American Journal of Neuroradiology 23:510-519, April 2002
© 2002 American Society of Neuroradiology
BRAIN
Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors
a Department of Neurology, Oregon Health and Science University, Portland, Oregon
b Department of Radiology, Oregon Health and Science University, Portland, Oregon
c Department of Neurosurgery, Oregon Health and Science University, Portland, Oregon
d Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon
e Department of Pathology, Oregon Health and Science University, Portland, Oregon
f Department of Otolaryngology, Oregon Health and Science University, Portland, Oregon
Address reprint requests to Edward A. Neuwelt, MD, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, L603, Portland, OR 97201
BACKGROUND AND PURPOSE: Ultrasmall superparamagnetic iron oxide particles result in shortening of T1 and T2 relaxation time constants and can be used as MR contrast agents. We tested four hypotheses by evaluating MR images of intracranial tumors after infusion of two iron oxide agents in comparison with a gadolinium chelate: 1) Ferumoxtran in contrast to ferumoxides can be used as an intravenous MR contrast agent in intracranial tumors; 2) ferumoxtran enhancement, albeit delayed, is similar to gadolinium enhancement; 3) ferumoxtran-enhanced MR images in contrast to gadolinium-enhanced MR images may be compared with histologic specimens showing the cellular location of iron oxide particles; 4) ferumoxtran can serve as a model for viral vector delivery.
METHODS: In 20 patients, ferumoxides and ferumoxtran were intravenously administered at recommended clinical doses. MR imaging was performed 30 minutes and 4 hours after ferumoxides infusion (n = 3), whereas ferumoxtran-enhanced MR imaging (n = 17) was performed 6 and 24 hours after infusion in the first five patients and 24 hours after infusion in the remaining 12. MR sequences were spin-echo (SE) T1-weighted, fast SE T2- and proton density–weighted, gradient-recalled-echo T2*-weighted, and, in four cases, echo-planar T2-weighted sequences. Representative regions of interest were chosen on pre- and postcontrast images to compare each sequence and signal intensity.
RESULTS: Despite some degree of gadolinium enhancement in all tumors, no significant T1 or T2 signal intensity changes were seen after ferumoxides administration at either examination time. Fifteen of 17 patients given ferumoxtrans had T1 and/or T2 shortening consistent with iron penetration into tumor. Histologic examination revealed minimal iron staining of the tumor with strong staining at the periphery of the tumors.
CONCLUSION: 1) Ferumoxtran can be used as an intravenous MR contrast agent in intracranial tumors, mostly malignant tumors. 2) Enhancement with ferumoxtran is comparable to but more variable than that with the gadolinium chelate. 3) Histologic examination showed a distribution of ferumoxtran particles similar to that on MR images, but at histology the cellular uptake was primarily by parenchymal cells at the tumor margin. 4) Ferumoxtran may be used as a model for viral vector delivery in malignant brain tumors.
This article has been cited by other articles:
 |
|
 |
|
  Y. J. Wu, L. L. Muldoon, C. Varallyay, S. Markwardt, R. E. Jones, and E. A. Neuwelt In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1698 - C1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.L. Muldoon, P.G. Tratnyek, P.M. Jacobs, N.D. Doolittle, G.A. Christoforidis, J.A. Frank, M. Lindau, P.R. Lockman, S.P. Manninger, Y. Qiang, et al. Imaging and Nanomedicine for Diagnosis and Therapy in the Central Nervous System: Report of the Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting AJNR Am. J. Neuroradiol., March 1, 2006; 27(3): 715 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Taschner, S. G. Wetzel, M. Tolnay, J. Froehlich, A. Merlo, and E. W. Radue Characteristics of Ultrasmall Superparamagnetic Iron Oxides in Patients with Brain Tumors Am. J. Roentgenol., December 1, 2005; 185(6): 1477 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Manninger, L. L. Muldoon, G. Nesbit, T. Murillo, P. M. Jacobs, and E. A. Neuwelt An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2290 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Murillo and E. Neuwelt USPIOs to Enhance the Diagnostic Potential of Ultrasound in Tumor and Other Inflammatory Lesions AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1305 - 1306. [Full Text] [PDF]
|
|
|
|
|
|
I. Nolte, G. H. Vince, M. Maurer, C. Herbold, R. Goldbrunner, L. Solymosi, G. Stoll, and M. Bendszus Iron Particles Enhance Visualization of Experimental Gliomas with High-Resolution Sonography AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1469 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Hunt, A. G. Bago, and E. A. Neuwelt Single-Dose Contrast Agent for Intraoperative MR Imaging of Intrinsic Brain Tumors by Using Ferumoxtran-10 AJNR Am. J. Neuroradiol., May 1, 2005; 26(5): 1084 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, et al. New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting Clin. Cancer Res., January 15, 2005; 11(2): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Anzai, C. W. Piccoli, E. K. Outwater, W. Stanford, D. A. Bluemke, P. Nurenberg, S. Saini, K. R. Maravilla, D. E. Feldman, U. P. Schmiedl, et al. Evaluation of Neck and Body Metastases to Nodes with Ferumoxtran 10-enhanced MR Imaging: Phase III Safety and Efficacy Study Radiology, September 1, 2003; 228(3): 777 - 788. [Abstract] [Full Text] [PDF]
|
|